Cybin Announces Positive CYB003 Data Demonstrating Significant Advantages Over Oral Psilocybin for Treatment of Mental HealthBusiness Wire • 11/08/21
Cybin Announces FDA Investigational New Drug Authorization of Cybin's Sponsored Feasibility Study Using Kernel Flow TechnologyBusiness Wire • 10/26/21